{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Durcan E"],"funding":["Bilimsel Araştirma Projeleri Birimi, Istanbul Üniversitesi"],"pagination":["236-246"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9060072"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["14(4)"],"pubmed_abstract":["Background
The aim of this study was to investigate the effects of sodium glucose cotransporter 2 inhibitors (SGLT2i) on the glomerulus through the evaluation of podocyturia in patients with diabetic kidney disease (DKD).Methods
The study population was composed of 40 male patients with type 2 diabetes mellitus; 22 of them received SGLT2i (SGLT2i group), and the others who did not were the control. The DKD-related parameters of patients were monitored before SGLT2i initiation, and then in the third and sixth month of the follow-up period. Patients' demographic, clinical, laboratory, and follow-up data were obtained from medical charts. Microalbuminuria was measured in 24-h urine. The number of podocytes in the urine was determined by immunocytochemical staining of two diffe"],"journal":["Journal of diabetes"],"pubmed_title":["Effects of SGLT2 inhibitors on patients with diabetic kidney disease: A preliminary study on the basis of podocyturia."],"pmcid":["PMC9060072"],"funding_grant_id":["33562"],"pubmed_authors":["Saygi HI","Bakir A","Sahin S","Karaca C","Durcan E","Dincer MT","Gonen MS","Sulu C","Ozkan S","Trabulus S","Guzel E","Seyahi N","Korkmaz OP","Ozkaya HM"],"additional_accession":[]},"is_claimable":false,"name":"Effects of SGLT2 inhibitors on patients with diabetic kidney disease: A preliminary study on the basis of podocyturia.","description":"Background
The aim of this study was to investigate the effects of sodium glucose cotransporter 2 inhibitors (SGLT2i) on the glomerulus through the evaluation of podocyturia in patients with diabetic kidney disease (DKD).Methods
The study population was composed of 40 male patients with type 2 diabetes mellitus; 22 of them received SGLT2i (SGLT2i group), and the others who did not were the control. The DKD-related parameters of patients were monitored before SGLT2i initiation, and then in the third and sixth month of the follow-up period. Patients' demographic, clinical, laboratory, and follow-up data were obtained from medical charts. Microalbuminuria was measured in 24-h urine. The number of podocytes in the urine was determined by immunocytochemical staining of two diffe","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Apr","modification":"2025-04-18T13:15:37.671Z","creation":"2025-04-06T22:49:14.028Z"},"accession":"S-EPMC9060072","cross_references":{"pubmed":["35229458"],"doi":["10.1111/1753-0407.13261"]}}